|
|
Description
For 14 years, the European Society of Gene Therapy
(ESGT) current ESGCT, has been actively involved in the evolution of the way we
understand and use of gene therapy and cell therapy. Gene therapy has
always been intertwined with cell therapy, even as early as in the late
1980s when the field started to emerge. Today our members are engaged
in research in these overlapping areas which cannot readily be
separated from one another. The members of our Society are leading the
world in cutting-edge research and laboratory techniques with gene
therapy, hematopoietic, mesenchymal and other stem or progenitor cells,
immunotherapies, dendritic cells, NK cells, T cells, pancreatic islets
and more. This wide range of target cells reflects a plethora of
diseases that are obvious targets for gene and cell therapy, including
cancer, diabetes, cardiovascular, neurologic, hereditary and infectious
diseases.
ESGT has a new name to reflect these integral
changes. The ESGT has become the European Society of Gene and Cell
Therapy (ESGCT). The Society facilitates ongoing educational workshops
and meetings, supports topical scientific networks and committees,
offers a forum for gene therapy, cell therapy and genetic vaccine
professionals to interact, and provides a voice in the regulatory arena.
Anonymous comments are disabled
|
|
|